Evgen Pharma (GB:TCF) has released an update.
TheraCryf plc, previously known as Evgen Pharma, has successfully integrated Chronos Therapeutics, expanding its drug development pipeline in oncology and neuropsychiatry. Shareholders of Chronos received over 62 million shares, and the transition included the appointment of new directors and the consolidation of various operational elements. The company aims to enhance shareholder value through a broadened pipeline that includes non-dilutive funding strategies for programs like SFX-01 in glioblastoma.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
